News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MediStem, Inc. (Formerly known as Medistem Laboratories, Inc.) Enters Collaboration With Boston Academic Teaching Hospital to Expand Preclinical Data in Type 1 Diabetes


7/29/2013 9:48:38 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, CA--(Marketwired - July 29, 2013) - Medistem, Inc. (PINKSHEETS: MEDS) announced today it has entered into collaboration with Reza Abdi, M.D., Transplant Nephrologist at Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. Under the collaboration, the Company will provide Dr. Abdi with its Endometrial Regenerative Cells (ERCs) and it is expected that his research would support FDA clearance to initiate clinical trials to use ERCs as a treatment for Type 1 Diabetes. Currently, the Company has FDA clearance to initiate a dose-escalating Phase I clinical trial to use ERCs in patients with critical limb ischemia, a complication of diabetes.

"Currently there are no treatments that reverse Type 1 diabetes. ERCs have a great potential to emerge as a cell therapy for type 1 diabetes by blocking the pathological autoimmune process that is causative of the disease," said Dr. Abdi.

"An independent study conducted by the National Institutes of Health (NIH) has shown that our ERCs possess superior ability to modulate immune response as compared to other types of stem cells," furthermore, "In previous studies, ERCs have shown the ability to produce chemical signals that inhibit autoimmune conditions such as Type 1 diabetes and multiple sclerosis," said Alan J. Lewis, Ph.D., Chief Executive Officer of Medistem. "We are delighted to be working with Dr. Abdi as we believe this collaboration could lead to a breakthrough in the treatment of Type 1 Diabetes."

About Medistem, Inc.

Medistem, Inc. is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States. In January 2012, we announced the initiation of our RECOVER-ERC (Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy) Phase II clinical trial. This trial is being conducted at the Bakulev Scientific Center for Cardiovascular Surgery, Moscow, Russia. The trial is a 60 patient double blind placebo controlled study evaluating safety and efficacy of ERCs in end stage CHF patients.

Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem, Inc. These can be identified by the use of forward-looking words, such as "believes," "expects," "may," "intends," "anticipates," "plans," "estimates," or any other analogous or similar expressions intended to identify forward-looking statements. These forward-looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Contact:

John P. Salvador
(626) 644-6092
john.salvador@medisteminc.com



Help employers find you! Check out all the jobs and post your resume

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES